Did You Miss Adverum Biotechnologies’s (NASDAQ:ADVM) Impressive 257% Share Price Gain?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. To wit, the Adverum Biotechnologies, Inc. (NASDAQ:ADVM) share price has flown 257% in the last three years. Most would be happy with that. It’s also good to see the share price up 127% over the last quarter.

See our latest analysis for Adverum Biotechnologies

We don’t think Adverum Biotechnologies’s revenue of US$1,396,000 is enough to establish significant demand. As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. It seems likely some shareholders believe that Adverum Biotechnologies has the funding to invent a new product before too long.

Companies that lack both meaningful revenue and profits are usually considered high risk. There is almost always a chance they will need to raise more capital, and their progress – and share price – will dictate how dilutive that is to current holders. While some companies like this go on to deliver on their plan, making good money for shareholders, many end in painful losses and eventual de-listing. Some Adverum Biotechnologies investors have already had a taste of the sweet taste stocks like this can leave in the mouth, as they gain popularity and attract speculative capital.

When it last reported its balance sheet in March 2019, Adverum Biotechnologies had cash in excess of all liabilities of US$157m. While that’s nothing to panic about, there is some possibility the company will raise more capital, especially if profits are not imminent. Given the share price has increased by a solid 53% per year, over 3 years, its fair to say investors remain excited about the future, despite the potential need for cash. You can click on the image below to see (in greater detail) how Adverum Biotechnologies’s cash levels have changed over time.

NasdaqGM:ADVM Historical Debt, June 29th 2019
NasdaqGM:ADVM Historical Debt, June 29th 2019

It can be extremely risky to invest in a company that doesn’t even have revenue. There’s no way to know its value easily. One thing you can do is check if company insiders are buying shares. If they are buying a significant amount of shares, that’s certainly a good thing. Luckily we are in a position to provide you with this free chart of insider buying (and selling).

A Different Perspective

It’s nice to see that Adverum Biotechnologies shareholders have gained 124% (in total) over the last year. That gain actually surpasses the 53% TSR it generated (per year) over three years. These improved returns may hint at some real business momentum, implying that now could be a great time to delve deeper. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Adverum Biotechnologies by clicking this link.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.